NYSE: CYBN - Cybin Inc.

Yield per half year: -24.41%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Cybin Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Cybin Inc.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in in preclinical stage to treat neuroinflammation.

more details
It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2019-09-13
ISIN CA23256X1006
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Сайт https://www.cybin.com
Цена ао 7.01
Change price per day: -4.27% (7.02)
Change price per week: -8.07% (7.31)
Change price per month: -18.64% (8.26)
Change price per 3 month: -26.56% (9.15)
Change price per half year: -24.41% (8.89)
Change price per year: +1 501.53% (0.4196)
Change price per 3 year: +772.73% (0.77)
Change price per 5 year: +3 307.71% (0.1972)
Change price per year to date: -29.49% (9.53)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.6298 10
P/E 0 0
EV/EBITDA 0.3199 10
Total: 5

Efficiency

Title Value Grade
ROA, % -40.45 0
ROE, % -42.43 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0037 10
Total: 8.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -818600 0
Yield EPS, % 32682.95 10
Total: 6
More

Institutions Volume Share, %
Point72 Asset Management, L.P. 30061112 4.04
Anson Funds Management LP 8924494 1.2
Alyeska Investment Group, L.P. 5683196 0.76
CVI Holdings, LLC 5225262 0.7
AdvisorShares Investments, LLC 1859181 0.25
PDS Planning, Inc 1153120 0.16
Propel Bio Management, LLC 850000 0.11
Simplify Asset Management, Inc. 500000 0.07
FNY Investment Advisers, LLC 402000 0.05
Lewis Asset Management, LLC 282000 0.04



Head Job title Payment Year of birth
Mr. Eric So L.L.B. Co-Founder, President & Executive Chairman 458.88k 1976 (49 years)
Mr. Douglas L. Drysdale Chief Executive Officer 613.44k 1970 (55 years)
Mr. Paul Glavine Co-Founder, Chief Growth Officer & Director 458.88k 1989 (36 years)
Mr. Greg Cavers Chief Financial Officer 242.09k 1971 (54 years)
Mr. Aaron Bartlone Chief Operating Officer 379.12k 1967 (58 years)
Mr. John Kanakis Co-Founder 704.03k 1981 (44 years)
Dr. Alex L. Nivorozhkin Ph.D. Chief Scientific Officer N/A 1960 (65 years)
Ms. Lori Challenger Chief Compliance, Ethics & Administrative Officer N/A
Mr. Gabriel Fahel Chief Legal Officer & Corporate Secretary N/A 1976 (49 years)
Mr. George Tziras Chief Business Officer & Director 1981 (44 years)

Address: Canada, Toronto, 100 King Street West - open in Google maps, open in Yandex maps
Website: https://www.cybin.com